PepperLedger
COMPOUND LIBRARY·QUERCETIN
COMPOUND PROFILE · PEPPERLEDGER

Quercetin

Type
Natural polyphenol flavonoid — widely distributed in plant foods including onions, apples, capers, berries, and green tea
Class
Senolytic (in D+Q combination) · Senomorphic (reduces SASP independently) · Anti-inflammatory · PCSK9 inhibitor · Mast cell stabiliser · Zinc ionophore · Antiviral
Administration
Oral capsule · Quercetin phytosome (Quercefit) has approximately 20x better bioavailability than standard quercetin — the preferred form for systemic applications
Half-life
Variable — quercetin and its metabolites have complex pharmacokinetics; phytosome formulation significantly extends plasma exposure
Most studied use
Senolytic combination with dasatinib · Daily anti-inflammatory supplement · Cardiovascular health · Allergy and mast cell stabilisation · Antiviral support
Regulatory status
Dietary supplement — GRAS; widely available OTC without prescription
Human evidence
Good — multiple RCTs for blood pressure, lipids, and allergic conditions; senolytic evidence from D+Q combination trials
Preclinical evidence
Strong — foundational Zhu 2015 Aging Cell paper established the D+Q senolytic mechanism

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is quercetin?

Quercetin is one of the most versatile compounds in the longevity supplement stack — it does several genuinely useful things simultaneously. Most people first encounter it as the non-prescription half of the D+Q senolytic combination (where it works alongside dasatinib to clear senescent cells). But quercetin has a rich independent pharmacology that makes it worth understanding on its own terms, not just as a dasatinib companion.

As a standalone daily supplement, quercetin’s most clinically important properties are: anti-inflammatory (NF-κB inhibition, reducing pro-inflammatory cytokine production), PCSK9 inhibition (the same cholesterol-reducing mechanism as expensive injectable biologics), mast cell stabilisation (relevant for histamine intolerance, allergies, and MCAS), antiviral activity via zinc ionophore function (quercetin carries zinc into cells where it inhibits viral RNA polymerase), and senomorphic effects (reducing the inflammatory secretory output of senescent cells without necessarily killing them). These independent properties are why many users take quercetin daily rather than only during D+Q senolytic pulses.

As a senolytic in the D+Q combination, quercetin contributes PI3K inhibition and BCL-XL suppression that complement dasatinib’s kinase inhibition, covering a broader range of senescent cell types than either compound alone. Quercetin’s standalone senolytic activity is real but weaker than fisetin as a standalone agent — it’s the combination with dasatinib that produces the strongest clinical senolytic data.

Bioavailability is the key practical consideration. Standard quercetin has approximately 1% oral bioavailability due to limited solubility and rapid gut metabolism. Quercetin phytosome (quercetin complexed with sunflower lecithin phospholipids, branded as Quercefit) achieves approximately 20x higher plasma quercetin levels than standard quercetin at the same dose. For any application where systemic quercetin levels matter — cardiovascular, senolytic — phytosome is strongly preferred.

How it works

Senolytic — PI3K and BCL-XL Inhibition

In the D+Q protocol, quercetin contributes two primary mechanisms: PI3K/AKT survival pathway inhibition (reducing the pro-survival signalling that senescent cells depend on) and BCL-XL inhibitory activity (reducing the anti-apoptotic protein that keeps senescent cells alive). These complement dasatinib’s kinase inhibition, covering senescent cell types that dasatinib does not fully address alone — particularly senescent human umbilical vein endothelial cells and NK cells.

Senomorphic — SASP Reduction

Beyond killing senescent cells, quercetin reduces the inflammatory secretory output of senescent cells that remain — the senomorphic effect. It inhibits NF-κB and reduces SASP factors including IL-6, IL-1β, TNF-α, and MMP-3. This daily anti-inflammatory effect on SASP is relevant even for users who do not run formal D+Q senolytic pulses — regular quercetin supplementation may reduce the chronic low-grade inflammation driven by accumulating senescent cells.

PCSK9 Inhibition — Cardiovascular

Quercetin inhibits PCSK9 expression and activity — the same target as evolocumab and alirocumab (injectable drugs costing thousands of dollars annually). By reducing PCSK9, quercetin allows LDL receptors to persist longer on hepatocyte surfaces, increasing LDL clearance from circulation. This positions quercetin alongside berberine as an accessible oral mechanism for reducing LDL beyond statin therapy.

Zinc Ionophore — Antiviral

Quercetin acts as a zinc ionophore — it facilitates zinc transport across cell membranes, raising intracellular zinc. Intracellular zinc inhibits viral RNA-dependent RNA polymerase (RdRp), the enzyme many viruses including coronaviruses and influenza use for replication. The quercetin + zinc combination became widely used during COVID-19 for this reason — the quercetin carries zinc into cells; zinc blocks viral replication.

What the research shows

STUDYJournal of the American Heart Association · 2016

Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials

Serban MC, Sahebkar A, Zanchetti A, et al.

A meta-analysis of 7 RCTs found quercetin supplementation significantly reduced systolic and diastolic blood pressure, with lipid improvements in subgroup analyses — establishing cardiovascular benefit at 150-500 mg/day and supporting the PCSK9 inhibition mechanism.

View on PubMed →
STUDYAging Cell · 2015

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs

Zhu Y, Tchkonia T, Pirtskhalava T, et al.

The foundational senolytic screening paper that identified quercetin as senolytic against specific cell types and established that the D+Q combination provides much broader senescent cell coverage than either compound alone — the mechanistic basis for the D+Q protocol used in human trials.

View on PubMed →
WHAT THE RESEARCH SHOWS
KNOWN
  • Blood pressure and lipid improvements demonstrated in human RCTs (meta-analysis)
  • Senolytic activity in specific cell types; D+Q combination covers broader range
  • PCSK9 inhibition mechanism characterized
  • Zinc ionophore mechanism for antiviral activity
  • Standard quercetin has ~1% bioavailability; phytosome achieves ~20x higher plasma levels
?UNCERTAIN
  • ?Standalone senolytic efficacy in humans vs. the D+Q combination
  • ?Optimal daily dose for senomorphic vs. cardiovascular effects
  • ?Long-term effects at supplemental doses

What the community reports

The quercetin community splits into two distinct use patterns — daily low-dose users and periodic high-dose D+Q practitioners — with meaningful overlap.

Two distinct protocols: 250-500 mg daily (anti-inflammatory, cardiovascular, mast cell) vs. 1000 mg intermittent as part of D+Q senolytic pulses — these are different interventions serving different goals
Allergy and MCAS: quercetin's mast cell stabilisation makes it a staple for users with histamine intolerance — many report meaningful reduction in allergic symptoms within 2-4 weeks of daily use
The zinc combination: quercetin + zinc (15-25 mg elemental zinc) taken together for antiviral support — the ionophore mechanism requires zinc to be present for the antiviral effect
Phytosome preference: experienced users specifically seek quercetin phytosome (Quercefit) — standard quercetin is considered largely ineffective at typical doses due to bioavailability limitations
Fat timing: quercetin absorption improves significantly with a fat-containing meal even for standard forms

Common misconceptions

"Any quercetin supplement works the same."

REALITY

Standard quercetin has ~1% oral bioavailability. Quercetin phytosome (Quercefit) achieves approximately 20x higher plasma quercetin at the same dose. For cardiovascular, senolytic, or any systemic application, the form matters significantly. Standard quercetin may provide some local gut benefit but delivers minimal systemic quercetin.

"Quercetin alone is as effective as D+Q for senolytics."

REALITY

Quercetin has standalone senolytic activity in specific cell types but is less potent as a standalone senolytic than fisetin and substantially less effective than the D+Q combination for broad senescent cell coverage. For serious senolytic protocols, D+Q (quarterly) or fisetin (monthly) remains preferred over quercetin alone. Daily quercetin is a senomorphic and anti-inflammatory maintenance compound, not a replacement for periodic senolytic pulses.

AI RESEARCHER PREVIEW
I take quercetin daily. Should I be doing D+Q pulses on top of that or does daily quercetin cover the senolytic angle?
Daily quercetin does something different from a D+Q pulse - you're getting the senomorphic and anti-inflammatory benefits (SASP reduction, NF-kB inhibition, mast cell stabilisation) continuously, which is genuinely valuable. But quercetin alone isn't replicating the senolytic depth of the D+Q combination. The dasatinib component covers cell types that quercetin alone doesn't handle well - particularly endothelial cells and certain immune cell populations. So the honest answer is they're complementary: daily quercetin (phytosome form for bioavailability) for ongoing anti-inflammatory maintenance, D+Q quarterly if you want a proper senolytic pulse. They're not redundant - the D+Q protocol uses high-dose quercetin for 2-3 consecutive days precisely because you need systemic peak levels for the senolytic effect. What dose and form are you using for daily quercetin?
CONTINUE IN THE APP

Open PepperLedger to track your quercetin protocol →

Free to join. No credit card. Ask the Coach about quercetin dosing, the D+Q senolytic protocol, and mast cell stabilisation.

Free to join · No credit card · 23-day Pro trial included